The update on INM-089 by InMed Pharmaceuticals indicates significant progress in their drug development pipeline, which could lead to increased investor interest and potential stock price appreciation in the short term. The focus on a treatment for dry age-related macular degeneration, a condition with substantial unmet medical needs, underscores the potential market impact and relevance of this development.